Search & Analyze

Piramal Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.piramalpharma.com BSE: 543635NSE: PPLPHARMA

₹190.85BSE2.18%

23 Oct, 4:01 PM

₹190.85

₹25.41K Cr

0.00

3.17

-4.04%

₹194.70

₹185.70

₹231.85

₹132.50

Customise metrics bar

Piramal Pharma Ltd. (PPLPHARMA) share price closed at ₹190.85 on the BSE on Friday, October 23, 2026, down by 2.18% from its of ₹195.10. In that session PPLPHARMA reached a of 194.70 and of 185.70. The for the session was 189.86. The stands at 206.78 and is at 175.91. Looking at , the stock ended the session moving sideways.

Stock Overview

Symbol

PPLPHARMA

₹193.75

₹195.10

₹189.86

₹206.78

Price 7.70% below

₹175.91

Price 8.49% above

57.22% of range

₹185.70₹194.70

58.73% of range

₹132.50₹231.85

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
Piramal Pharma Ltd. PPLPHARMA	190.85	0.00	25,408.78	0.00	-69.39	15.07%	2,269.92	17.39%	1.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,951.14	2,241.75	2,204.22	2,754.07	1,933.71	2,043.72	2,139.87	2,751.77	2,269.92
Expenses	1,746.65	1,900.14	1,866.48	2,193.08	1,827.01	1,885.03	1,944.14	2,291.26	2,074.72
	204.49	341.61	337.74	560.99	106.70	158.69	195.73	460.51	195.20
	10.48%	15.24%	15.32%	20.37%	5.52%	7.76%	9.15%	16.74%	8.60%
	19.54	61.11	12.13	42.03	79.14	65.60	2.13	-129.71	89.41
Interest	106.96	107.64	103.31	103.68	86.15	82.42	89.24	82.99	88.08
	184.55	192.22	196.81	242.76	197.28	202.84	212.74	218.38	223.55
	-45.08	120.12	66.80	272.80	-79.02	-46.18	-93.86	43.01	-7.46
	-96.63%	81.19%	94.49%	43.73%	-3.39%	-114.85%	-45.10%	120.51%	-830.16%
	-88.64	22.59	3.68	153.50	-81.70	-99.22	-136.19	-8.82	-69.39
	-0.67	0.17	0.03	1.16	-0.62	-0.75	-1.03	-0.07	-0.52

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	7,305.82	8,106.90	9,421.02	10,619.99	10,518.28
	6,559.10	7,081.55	8,171.16	9,151.18	8,869.08
EXPENDITURE :
Increase/Decrease in Stock	55.23	68.64	-198.60	-241.41	-187.84
Raw Material Consumed	2,396.03	2,634.66	3,152.60	3,473.06	3,426.38
Power & Fuel Cost	163.56	207.81	241.59	267.16	260.18
Employee Cost	1,588.83	1,896.35	2,029.50	2,307.47	2,415.92
Other Manufacturing Expenses	589.03	674.10	731.64	774.18	808.39
General and Administration Expenses	428.49	472.78	542.00	563.04	592.71
Selling and Distribution Expenses	317.81	372.59	359.75	398.11	437.58
Miscellaneous Expenses	70.46	126.38	142.17	191.70	223.27
	5,609.44	6,453.31	7,000.65	7,733.31	7,976.59
Operating Profit (Excl OI)	949.66	628.24	1,170.51	1,417.87	892.49
	275.80	225.11	201.14	161.77	242.43
	1,225.46	853.35	1,371.65	1,579.64	1,134.92
Interest	198.25	344.18	448.49	421.59	340.80
PBDT	1,027.21	509.17	923.16	1,158.05	794.12
	586.18	676.69	740.57	816.34	831.24
Profit Before Taxation & Exceptional Items	441.03	-167.52	182.59	341.71	-37.12
Exceptional Income / Expenses	-15.08	-6.96	-62.79		-196.14
	484.98	-120.15	179.29	414.64	-176.06
Provision for Tax	109.02	66.31	161.47	323.51	149.88
	375.96	-186.46	17.82	91.13	-325.94
Extra items			0.00	0.00	0.00
Consolidated Net Profit	375.96	-186.46	17.82	91.13	-325.94
Profit Balance B/F	832.56	1,158.85	956.42	970.67	1,049.32
Appropriations	1,208.52	972.39	974.24	1,061.80	723.38
Equity Dividend %			1.10%	1.40%
	3.17	-1.56	0.13	0.69	-2.46
Adjusted EPS	3.10	-1.53	0.13	0.69	-2.46

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	1,185.91	1,193.32	1,322.95	1,324.35	1,327.16
Share Warrants & Outstandings			27.47	62.16	72.79
Total Reserves	5,510.69	5,580.18	6,560.95	6,738.96	6,762.67
Reserve excluding Revaluation Reserve	5,510.69	5,580.18	6,560.95	6,738.96	6,762.67
Revaluation reserve		0.00	0.00
	6,696.60	6,773.50	7,911.37	8,125.47	8,162.62
Secured Loans	2,622.14	3,383.54	2,483.75	3,214.07	4,299.97
Deferred Tax Assets / Liabilities	-105.26	-129.99	-157.32	-144.78	-156.55
Other Long Term Liabilities	240.36	282.48	285.89	274.77	291.68
Long Term Provisions	145.34	275.97	32.32	48.66	94.31
Total Non-Current Liabilities	2,902.58	3,812.00	2,644.64	3,392.72	4,529.41
Trade Payables	1,026.35	1,192.71	1,538.37	1,533.77	2,479.11
Other Current Liabilities	1,242.76	1,305.30	1,575.68	1,184.72	1,478.61
Short Term Borrowings	658.76	1,302.29	1,171.38	995.32	747.80
Short Term Provisions	190.14	50.74	83.87	136.75	169.22
Total Current Liabilities	3,118.01	3,851.04	4,369.30	3,850.56	4,874.74
Total Liabilities	12,717.19	14,436.54	14,925.31	15,368.75	17,566.77
Gross Block	9,510.49	10,842.12	12,137.48	13,117.63	14,904.70
Less: Accumulated Depreciation	2,631.31	3,373.52	4,147.55	4,984.20	6,213.64
Less: Impairment of Assets					7.10
Net Block	6,879.18	7,468.60	7,989.93	8,133.43	8,683.96
Capital Work in Progress	673.15	852.93	565.70	489.12	799.17
Non Current Investments	216.77	211.87	240.26	271.09	305.01
Long Term Investment	216.77	211.87	240.26	271.09	305.01
Long Term Loans & Advances	296.97	493.98	114.85	91.08	155.18
Other Non Current Assets	0.04	0.04	0.00	14.97	14.72
Total Non-Current Assets	8,565.30	9,593.07	9,460.84	9,487.47	10,258.66
Currents Investments	50.40	427.11	144.69	19.56	131.78
Inventories	1,388.80	1,681.37	2,175.88	2,312.70	3,064.44
Sundry Debtors	1,785.28	1,799.34	2,134.43	2,349.52	2,157.67
Cash and Bank	328.99	307.56	482.56	501.46	1,223.64
Other Current Assets	93.66	140.24	81.93	134.87	144.80
Short Term Loans and Advances	504.76	487.85	444.98	563.17	585.78
Total Current Assets	4,151.89	4,843.47	5,464.47	5,881.28	7,308.11
Net Current Assets (Including Current Investments)	1,033.88	992.43	1,095.17	2,030.72	2,433.37
Total Assets	12,717.19	14,436.54	14,925.31	15,368.75	17,566.77
Contingent Liabilities	44.94	57.32	61.43	99.76	95.72
Total Debt	4,023.28	5,504.77	4,558.86	4,720.27	5,495.48
	56.47	56.76	59.59	60.89	60.96
Adjusted Book Value	55.15	55.44	59.59	60.89	60.96

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	441.03	-160.56	119.80	341.71	-233.26
Adjustment	787.10	1,135.53	1,275.88	1,372.66	1,569.45
Changes In working Capital	-292.29	-302.08	-234.30	-487.72	526.56
Cash Flow after changes in Working Capital	935.84	672.89	1,161.38	1,226.65	1,862.75
Cash Flow from Operating Activities	766.42	483.89	1,004.54	892.30	1,652.60
Cash Flow from Investing Activities	-1,812.10	-1,338.78	-434.01	-477.46	-826.03
Cash Flow from Financing Activitie	794.19	817.79	-422.36	-440.83	-38.98
Net Cash Inflow / Outflow	-251.49	-37.10	148.17	-25.99	787.59
Opening Cash & Cash Equivalents	261.97	85.18	53.23	219.19	182.32
Cash & Cash Equivalent on Amalgamation / Take over / Merger	76.74
Effect of Foreign Exchange Fluctuations	-2.04	5.15	17.79	-10.88	6.35
Closing Cash & Cash Equivalent	85.18	53.23	219.19	182.32	976.26

Ratios

Valuation

3.17

23.66

2.76

-2.36

60.13

Profitability

-4.04

1.24

-1.98

8.49

-3.10

Leverage & Liquidity

0.68

1.50

0.48

Returns

0.00

0.64

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	34.95	34.95	34.95	34.95	34.86	34.86	34.86	34.86	34.80	34.80
	44.37	45.53	45.78	46.26	45.11	45.16	45.35	45.79	27.09	28.09
	20.69	19.52	19.27	18.78	20.03	19.98	19.79	19.36	38.11	37.11
	65.05	65.05	65.05	65.05	65.14	65.14	65.14	65.14	65.20	65.20
No. of Shareholders	3,06,398	3,59,751	4,18,442	4,32,843	4,58,430	4,62,511	4,53,830	4,50,661	4,61,096	4,13,197

Mutual Funds Invested(103)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 48 active funds hold 12.24% in Piramal Pharma Ltd., contributing to ₹3.37K Cr of holdings

Fund				As of
HD HDFC Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	1,483.57	1.37	7,18,36,476	Sep '26
NI Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care	205.22	2.24	99,37,272	Sep '26
ID Bandhan Small Cap Fund - Growth - Direct PlanSmall cap Fund	204.39	0.57	98,96,924	Sep '26
FT Franklin India Opportunities Fund - Growth - Direct PlanEquity - Thematic Fund - Other	127.10	1.33	61,54,389	Sep '26
BF Bajaj Finserv Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund	124.36	1.46	60,21,499	Sep '26
CR Canara Robeco Small Cap Fund - Growth - Direct PlanSmall cap Fund	116.28	0.83	56,30,453	Sep '26
FT Franklin India Small Cap Fund - Growth - Direct PlanSmall cap Fund	105.52	0.74	51,09,343	Sep '26
NI Nippon India Small Cap Fund - Growth - Direct PlanSmall cap Fund	103.06	0.13	49,90,259	Sep '26
IP ICICI Prudential Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	94.28	0.50	45,65,035	Sep '26
CR Canara Robeco Aggressive Hybrid Fund - Growth - Direct PlanHybrid - Aggressive Hybrid Fund	65.05	0.60	31,50,000	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-16	Board Meeting	Quarterly Results
2026-07-20	Board Meeting	Quarterly Results
2026-07-03	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Piramal Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Maneesh Sharma

Company Secretary & Compliance Officer

—

Nandini Piramal

Chairperson

₹8.43 Cr

Mar '26

Peter DeYoung

Whole Time Director

₹8.50 Cr

Mar '26

Vivek Valsaraj

Executive Director & Chief Financial Officer

₹4.55 Cr

Mar '26

Jairaj Purandare

Non Executive Independent Director

₹54.00 L

Mar '26

Sridhar Gorthi

Non Executive Independent Director

₹49.00 L

Mar '26

Peter Stevenson

Non Executive Independent Director

₹47.50 L

Mar '26

Vibha Paul Rishi

Non Executive Independent Director

₹50.50 L

Mar '26

Nathalie Leitch

Non Executive Director

₹46.50 L

Mar '26

Amit Jain

Non Executive Director

—

Amit Soni

Non Executive Independent Director

₹7.01 L

Mar '26

PPLPHARMA Latest News

News

10 of 10 articles

COMPANY15 Sept 2026 · 12:50

USFDA concludes GMP inspection of Piramal Pharma’s Morpeth facility

At the conclusion of the inspection, the USFDA issued a Form-483, with 7 observations

EQUITY18 Aug 2026 · 15:03

Piramal Pharma soars on completing acquisition of additional 40.67% stake in Yapan Bio

Consequent to the above acquisition, Yapan has ceased to be an associate company and has become a subsidiary of the Company

COMPANY18 Aug 2026 · 14:58

Piramal Pharma completes acquisition of additional 40.67% stake in Yapan Bio

Consequent to the above acquisition, Yapan has ceased to be an associate company and has become a subsidiary of the Company

EQUITY17 Jul 2026 · 12:15

Piramal Pharma informs about disclosure

EQUITY9 Jul 2026 · 14:52

Piramal Pharma climbs on getting EIR from USFDA for Sellersville manufacturing facility

With the issuance of the EIR, the inspection has now been successfully closed by the USFDA

COMPANY9 Jul 2026 · 14:43

Piramal Pharma gets EIR from USFDA for Sellersville manufacturing facility

With the issuance of the EIR, the inspection has now been successfully closed by the USFDA

EQUITY3 Jun 2026 · 12:07

Piramal Pharma informs about updates

EQUITY3 Jun 2026 · 11:34

Piramal Pharma informs about updates

COMPANY18 May 2026 · 12:38

Piramal Pharma gets EIR from USFDA for Telangana manufacturing facility

The receipt of said EIR marks successful closure of the inspection

COMPANY11 May 2026 · 09:42

USFDA concludes GMP inspection at Piramal Pharma’s Sellersville facility

At the conclusion of the inspection, USFDA issued a Form-483, with three observations

PPLPHARMA

₹190.85

-2.18%